Table 3.
CAR-T formats *.
| CAR-T Format | Clinical Stage | Total | ||
|---|---|---|---|---|
| Phase I/II | Phase III | Approved | ||
| Autologous CAR-T **—Single CAR | 176 | 2 | 2 | 180 |
| Autologous CAR-T **—Multiple CARs for different targets or multiple CAR-Ts dosed in combination | 30 | 0 | 0 | 30 |
| Autologous CAR-NKT | 1 | 0 | 0 | 1 |
| Allogeneic CAR-T | 11 | 0 | 0 | 11 |
| Allogeneic CAR-NK or -NKT | 3 | 0 | 0 | 3 |
| Total | 221 | 2 | 2 | 225 |
* BiStro Biotech Consulting LLC database, locked 20 June 2019. Data obtained from Clinicaltrials.gov, literature papers, company websites, analyst reports and other sources. ** As far as can be ascertained from public documents, all of these appear to be based on αβ-T cells.